Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name TP53TG1
   Synonyms TP53TG1, LINC00096, NCRNA00096, P53TG1, P53TG1-D, TP53AP1, H_RG012D21.9
   Region GRCh38_7:87325225-87345515    Sequence
   Ensembl ENSG00000182165
   RefSeq NR_015381
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name non small cell lung cancer
   ICD-0-3 C34  M8046/3
   Methods qPCR, Western blot, luciferase reporter assay, RIP, in vitro knockdown etc.
   Sample cell line (HBE, A549), NSCLC tissue
   Expression Pattern down-regulated
   Function Description

TP53TG1 level was downregulated in NSCLC tissues and cell lines.Upregulated TP53TG1 enhanced cisplatin sensitivity and apoptosis of A549/DDP cells,while TP53TG1 depletion inhibited cisplatin sensitivity and apoptosis of A549 cells.TP53TG1 suppressed miR-18a expression in A549 cells.Moreover,TP53TG1-mediated enhancement effect on cisplatin sensitivity was abated following the restoration of miR-18a expression in A549/DDP cells, while si-TP53TG1-induced decrease of cisplatin sensitivity and apoptosis was counteracted by miR-18a inhibitor in A549 cells. Furthermore, TP53TG1 promoted PTEN expression via inhibiting miR-18a.Finally,TP53TG1 sensitized NSCLC cells to cisplatin in vivo.

   Pubmed ID 29588850
   Year 2018
   Title TP53TG1 enhances cisplatin sensitivity of non-small cell lung cancer cells through regulating miR-18a/PTEN axis.
   External Links
   Links for  TP53TG1 GenBank       HGNC       lncrnadb       Noncode
   Links for  non small cell lung cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.